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Abstract

Statement of the Problem

Numerous medications are available to treat depression,
yet many patients do not achieve remission or recovery of
their symptoms with traditional therapies alone. Folate
supplementation has been shown to be beneficial in the
treatment of depression when used in addition to
traditional prescription therapy. A literature review was
conducted to determine the effect of low folate levels on
depression and if supplementation with either folic acid or
L-methylfolate benefits this patient population. Key search
terms including folate, folate deficiency, methylfolate,
nutrition, and depression were used to perform searches of
multiple databases and journals including PubMed,
CINAHL, PsycInfo, and the American Journal of Psychiatry.
Studies such as the one conducted by Loria-Kohen et al.
(2013), demonstrated benefit in the use of folic acid
supplementation in lowering depression scores.
Researchers including Zajecka et al. (2016) have shown
that due to its ability to cross the blood brain barrier, Lmethylfolate is the better option in the treatment of
depression. Medical providers must determine the best
treatment plan based on an individuals personalized needs
while also considering the risks, benefits, testing options,
and cost of treatment.

Both the Practice Guideline for the Treatment of Patients with Major
Depressive Disorder (Gelenberg et al., 2010) and the American
Psychiatric Association list folate as a complementary treatment
which can be used in addition to traditional therapies. Neither of
these guidelines provides clear recommendations for the type of
supplement, dosage ranges, or monitoring that should be used when
supplementing with folate in the treatment of depression.

Introduction
The term folate is used to describe natural folates found in
foods, folic acid, folinic acid, and L-methylfolate. While
folate is readily available in many foods and supplements,
low levels of folate can occur due to poor dietary intake,
genetic mutations which effect folate methylation, poor
absorption in the gastrointestinal tract, excessive alcohol
intake, and as a side effect to certain medications (Shelton,
Manning, & Barrentine, 2013). L-methylfolate is the usable
form of folate and is the only form that can cross the blood
brain barrier. Folate is also necessary for the production of
the neurotransmitters serotonin, norepinephrine, and
dopamine, which are important for maintaining general
and mental health. (DynaMed, 2016)
The monoamine hypothesis of depression predicts that
depression is the result of low levels of norepinephrine,
dopamine and/or serotonin in the brain (McCance, K. L. &
Huether, S. E., 2014). According to the Center for Disease
Control and Prevention (CDC), more than 15 million adults
have experienced depression within the last year. For those
patients who seek treatment, many must try multiple
medications to find one which is both effective and has few
or tolerable side effects. Although the relationship between
folate and depression was first recognized in the 1960’s,
folate supplementation is not routinely recommended or
prescribed for the treatment of depression.

Research Questions

Methylfolate supplementation for the treatment of
depression.
Shelton, Manning, & Barrentine (2013) reported that 67.9% of
study participants had some response to adjunctive treatment
with L-methylfolate and 45.7% of participants achieved
remission of depressive symptoms. Wade, Kindermann, Hou,
and Thase (2014) showed that the addition of L-methylfolate is
more effective than the addition of second-generation
antipsychotics (SGAs) for the treatment of depression. The Lmethylfolate group was shown to have higher rates of
adherence, lower depression-related costs, and lower general
healthcare cost compared to patients taking SGA’s (p< 0.001).

• In patients treated for depression using traditional antidepressants,
should routine folate supplementation be considered as an
adjunctive therapy for the reduction of depressive symptoms?
• As an adjunct in treating depression, is folic acid or L-methylfolate
more effective?

Literature Review

Folate intake and supplementation for the treatment of
depression.
Loria-Kohen et al. (2013) found a positive correlation between
folic acid supplementation, decreased homocysteine levels, and
decreased levels of depression. As total folate intake increased in
the supplemented group, their Beck Depression Inventory scores
decrease (r= -0.581, p < 0.05). In contrast, The FolATED study
showed that patients treated with 5 mg of folic acid provided no
clinical benefit in the treatment of depression; adjusted difference
between patients treated with folic acid and those with placebo at
25 weeks was insignificant at 1.27 (95% CI; p = 0.27).

• Without clear guidelines, the decision of whether or not to
recommend folate supplementation is a provider decision
based on each unique patient presentation.
• Providers must consider the potential causes of low folate
levels including poor diet, genetic mutations which affect
folate methylation, conditions which cause poor absorption in
the gastrointestinal tract, excessive alcohol intake, and
medication side effects.
• Cost and applicability of testing
• Cost varies widely based on insurance and lab.
• If only those patients with a clear folate deficiency are
treated, some patients who may benefit from folate
supplementation would not be included.
• Financial cost of supplementation
• Folic acid 5 mg
• $11.95 for a 100-day supply.
• L-methylfolate 15 mg
• $140 for a 30-day supply of Deplin
• $174 for a 90-day supply with Rx card
• $79.00 for a 90-day supply of generic
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Folate methylation and neurotransmitters
Miller (2008) discussed that folate is an essential nutrient involved
in synthesis of neurotransmitters such as dopamine and serotonin
and thus is thought to play an important role in mood and
cognition. Figure 1, published by Fava & Micshoulon (2009),
provides a good illustration of the various types of folate and the
methylation steps necessary for the formation of L-methylfolate.

Applicability to Clinical Practice

Discussion
The literature supports routine folate supplementation as an
adjunctive treatment for depression. These studies also verify
the relative safety of folate supplementation while showing the
inefficiency of testing for folate deficiency. Based on the review
of literature, L-methylfolate supplementation is superior to
supplementation with folic acid in the treatment of depression
when used in addition to traditional antidepressant
medications. Also, whether supplementing with folic acid or Lmethylfolate, the best results were seen with high dose
supplementation. Common limitations of current research
include small sample sizes and the use of retrospective methods
to gather data. Additional long-term studies are needed to
confirm the benefits, assess for potential risks, and determine
other contributing factors that may affect the decision whether
or not to supplement depressed patients with L-methylfolate or
folic acid.
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